A detailed history of State Street Corp transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 836,914 shares of IPSC stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
836,914
Previous 779,591 7.35%
Holding current value
$1.05 Million
Previous $1.99 Million 27.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.44 - $3.29 $82,545 - $188,592
57,323 Added 7.35%
836,914 $1.43 Million
Q2 2024

Aug 14, 2024

BUY
$2.46 - $4.05 $724,157 - $1.19 Million
294,373 Added 60.67%
779,591 $1.99 Million
Q1 2024

May 15, 2024

BUY
$3.19 - $5.32 $117,159 - $195,387
36,727 Added 8.19%
485,218 $2.03 Million
Q4 2023

Feb 14, 2024

BUY
$1.28 - $3.32 $2,457 - $6,374
1,920 Added 0.43%
448,491 $1.49 Million
Q3 2023

Nov 14, 2023

SELL
$2.0 - $3.23 $16,440 - $26,550
-8,220 Reduced 1.81%
446,571 $893,000
Q2 2023

Aug 14, 2023

BUY
$2.91 - $3.53 $250,085 - $303,368
85,940 Added 23.3%
454,791 $1.44 Million
Q1 2023

May 15, 2023

BUY
$3.4 - $5.11 $89,012 - $133,779
26,180 Added 7.64%
368,851 $1.28 Million
Q4 2022

Feb 14, 2023

BUY
$4.84 - $11.58 $96,819 - $231,646
20,004 Added 6.2%
342,671 $1.76 Million
Q3 2022

Nov 15, 2022

BUY
$8.57 - $13.1 $454,475 - $694,706
53,031 Added 19.67%
322,667 $3.19 Million
Q2 2022

Aug 15, 2022

BUY
$7.96 - $12.43 $378,919 - $591,705
47,603 Added 21.44%
269,636 $2.27 Million
Q1 2022

May 16, 2022

BUY
$11.62 - $15.92 $393,743 - $539,449
33,885 Added 18.01%
222,033 $2.8 Million
Q4 2021

Feb 14, 2022

BUY
$13.93 - $23.62 $548,646 - $930,297
39,386 Added 26.48%
188,148 $2.98 Million
Q3 2021

Nov 15, 2021

BUY
$20.8 - $31.93 $3.09 Million - $4.75 Million
148,762 New
148,762 $3.74 Million

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $74.2M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.